Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes (CONFI-DIAB)

C

Central Hospital, Nancy, France

Status

Unknown

Conditions

Glucose Metabolism Disorders
Diabetes Mellitus
Metabolic Disease
Coronavirus Infection

Treatments

Other: no intervention

Study type

Observational

Funder types

Other

Identifiers

NCT04485351
2020PI137

Details and patient eligibility

About

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the COVID-19 (Coronavirus Disease-2019) in December 2019 has led to an unprecedented international health situation. Exceptional measures have been taken by public authorities worldwide in order to slow the spread of the virus and prevent healthcare systems from becoming overloaded. In France, a national lockdown has been established during approximately 2 months to increase social distancing and restrict population movements. Hospital routine care appointments have been cancelled, in order to reallocate medical resources towards COVID-19 units and limit contacts between patients within hospitals or waiting rooms. While the virus itself, the disease and potential treatments are currently extensively studied, little data are available on the effect of these public health decisions on the management of a chronic condition such as diabetes. The French regional CONFI-DIAB study aims at assessing the collateral impact of routine care cancellation during the national lockdown due to COVID-19 in patients with a chronic condition such as diabetes. Special attention will be given to metabolic control and access to health care. This cross-sectional study should provide information on the consequences of a global lockdown and the associated routine care cancellation on the management of diabetes, and inform future decision making in the event of a new pandemic.

Enrollment

700 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients
  • Patient with diabetes known for at least 6 months before inclusion
  • Patient followed by a specialist physician from the University Hospital of Nancy for routine care within the 6 months prior to the lockdown.
  • Patient who was assessed for prioritization of care following the end of the lockdown by the department of endocrinology, diabetology and nutrition

Exclusion criteria

  • Subjects opposed to the use of their data
  • Minors, adults under guardianship, protected persons

Trial design

700 participants in 1 patient group

Diabetic patients from the University Hospital of Nancy
Treatment:
Other: no intervention

Trial contacts and locations

0

Loading...

Central trial contact

Lisa Ludwig, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems